Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Raltegravir Intensification on HIV-1-infected Subjects with Complete Viral Suppression under Protease Inhibitor Monotherapy
2011-004464-30Phase 3Active
- Sponsor
- IrsiCaixa
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of raltegravir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by IrsiCaixa. Primary endpoint: Change in HIV-1 episomal DNA (2-LTR circles). Started Oct 2011; status: active.
02
Drugs
raltegravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2011-004464-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004464-30.